Switching from ustekinumab to guselkumab for psoriasis
Part of Skin clinical trials.
This study is testing a medicine called guselkumab (Tremfya) for people with psoriasis who are already taking another biologic medicine, ustekinumab, but need to switch. The goal is to see how well guselkumab works in real-world use.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have moderate to severe plaque psoriasis that needs treatment.
- You are currently taking ustekinumab (Stelara or a biosimilar) and your doctor says it's time to switch to a different medicine called guselkumab (Tremfya).
- You have not used guselkumab before.
- You are not pregnant or breastfeeding.
- You are not already in another clinical study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a higher dose of guselkumab (a biologic medicine) given less frequently works as well as the standard dose for treating moderate-to-severe plaque psoriasis. The goal is to find a dosing schedule that is both effective and convenient for patients.
This trial studies how guselkumab works for people with long-lasting, more severe psoriasis and signs that may affect joints. It may help by improving psoriasis symptoms and possibly reducing related inflammation, while researchers track safety and outcomes.
This study tracks how well patients stick with guselkumab, a biologic injection medication for moderate-to-severe plaque psoriasis. Researchers want to understand real-world treatment outcomes in Romania to help improve psoriasis care.
This trial is for people with skin psoriasis who are already taking guselkumab (Tremfya) and have their shots spaced 9 weeks or longer apart. Researchers will see how well the skin is controlled with this longer interval.
This study tests guselkumab, a medication that reduces inflammation in the gut, for people with moderate-to-severe Crohn's disease or ulcerative colitis who haven't previously tried certain similar biologic drugs. The goal is to see how well it works and is tolerated in real-world use.
This trial tests whether switching from the drug ustekinumab to another drug called guselkumab can help people with active inflammatory bowel disease (IBD) who didn't get enough benefit from ustekinumab. It focuses on people with Crohn's disease or ulcerative colitis who still have signs of inflammation in their gut.
Hear when a new Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.